Caribou Biosciences, Inc. (CRBU)
NASDAQ: CRBU · Real-Time Price · USD
0.7675
-0.0175 (-2.23%)
At close: Apr 4, 2025, 4:00 PM
0.7471
-0.0204 (-2.66%)
After-hours: Apr 4, 2025, 7:58 PM EDT
Caribou Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Cash & Equivalents | 16.29 | 51.16 | 58.34 | 240.42 | 15.95 | Upgrade
|
| Short-Term Investments | 193.24 | 277.67 | 189.33 | 135.41 | - | Upgrade
|
| Cash & Short-Term Investments | 209.54 | 328.83 | 247.66 | 375.83 | 15.95 | Upgrade
|
| Cash Growth | -36.28% | 32.77% | -34.10% | 2255.87% | -67.75% | Upgrade
|
| Accounts Receivable | 1.42 | 1.57 | 2.45 | 2.64 | 1.48 | Upgrade
|
| Other Receivables | 1.83 | 2.29 | 2.22 | 5.48 | 3.68 | Upgrade
|
| Receivables | 3.25 | 3.86 | 4.66 | 8.12 | 5.16 | Upgrade
|
| Prepaid Expenses | 4.81 | 4.94 | 6.37 | 3.85 | 1.82 | Upgrade
|
| Other Current Assets | 1.78 | 1.22 | 1.55 | 3.39 | 1.38 | Upgrade
|
| Total Current Assets | 219.38 | 338.84 | 260.25 | 391.19 | 24.31 | Upgrade
|
| Property, Plant & Equipment | 39.29 | 40.45 | 34.91 | 4.89 | 3.5 | Upgrade
|
| Long-Term Investments | 49.13 | 51.33 | 77.07 | 45.3 | 7.63 | Upgrade
|
| Other Long-Term Assets | 5.52 | 1.59 | 1.54 | 0.98 | 0.61 | Upgrade
|
| Total Assets | 313.31 | 432.21 | 373.77 | 442.36 | 36.05 | Upgrade
|
| Accounts Payable | 2.48 | 3.12 | 1.15 | 3.99 | 2.6 | Upgrade
|
| Accrued Expenses | 21.94 | 19.65 | 14.41 | 12.09 | 8.15 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | - | - | 0.65 | Upgrade
|
| Current Portion of Leases | 1.43 | 1.2 | 0.97 | - | - | Upgrade
|
| Current Unearned Revenue | 3.13 | 2.85 | 9.94 | 8.7 | 0.16 | Upgrade
|
| Other Current Liabilities | 1.68 | 1.48 | 1.67 | 1.05 | 0.82 | Upgrade
|
| Total Current Liabilities | 30.65 | 28.3 | 28.13 | 25.83 | 12.39 | Upgrade
|
| Long-Term Debt | - | - | - | - | 0.92 | Upgrade
|
| Long-Term Leases | 25.06 | 25.91 | 26.78 | - | 0.1 | Upgrade
|
| Long-Term Unearned Revenue | 3.32 | 6.1 | 15.95 | 22.03 | 0.94 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 0.55 | 0.56 | 0.38 | 0.48 | 0.16 | Upgrade
|
| Other Long-Term Liabilities | 0.79 | 2.94 | 1.65 | 6.19 | 3.66 | Upgrade
|
| Total Liabilities | 60.36 | 63.81 | 72.89 | 54.53 | 18.16 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0 | Upgrade
|
| Additional Paid-In Capital | 701.08 | 667.65 | 499.6 | 485.75 | 7.43 | Upgrade
|
| Retained Earnings | -448.39 | -299.29 | -197.22 | -97.79 | -30.87 | Upgrade
|
| Comprehensive Income & Other | 0.26 | 0.03 | -1.52 | -0.14 | - | Upgrade
|
| Total Common Equity | 252.95 | 368.4 | 300.87 | 387.83 | -23.44 | Upgrade
|
| Shareholders' Equity | 252.95 | 368.4 | 300.87 | 387.83 | 17.89 | Upgrade
|
| Total Liabilities & Equity | 313.31 | 432.21 | 373.77 | 442.36 | 36.05 | Upgrade
|
| Total Debt | 26.49 | 27.11 | 27.75 | - | 1.68 | Upgrade
|
| Net Cash (Debt) | 222.9 | 345.3 | 289.29 | 413.51 | 14.28 | Upgrade
|
| Net Cash Growth | -35.45% | 19.36% | -30.04% | 2796.73% | -71.03% | Upgrade
|
| Net Cash Per Share | 2.47 | 4.68 | 4.76 | 13.06 | 1.67 | Upgrade
|
| Filing Date Shares Outstanding | 93 | 90.31 | 61.3 | 60.66 | 10.39 | Upgrade
|
| Total Common Shares Outstanding | 92.38 | 88.45 | 61.03 | 60.26 | 9.71 | Upgrade
|
| Working Capital | 188.73 | 310.54 | 232.12 | 365.36 | 11.92 | Upgrade
|
| Book Value Per Share | 2.74 | 4.17 | 4.93 | 6.44 | -2.41 | Upgrade
|
| Tangible Book Value | 252.95 | 368.4 | 300.87 | 387.83 | -23.44 | Upgrade
|
| Tangible Book Value Per Share | 2.74 | 4.17 | 4.93 | 6.44 | -2.41 | Upgrade
|
| Machinery | 20.65 | 16.98 | 13.46 | 7.25 | 5.42 | Upgrade
|
| Construction In Progress | - | 8.2 | 0.99 | 0.01 | - | Upgrade
|
| Leasehold Improvements | 11.52 | 2.24 | 1.88 | 1.7 | 1.18 | Upgrade
|
Updated Mar 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.